Compare AbCellera Biologics Inc (ABCL) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Wheaton Precious Metals Corp — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Wheaton Precious Metals Corp trades at $107.75 (market cap $50.76B). The key difference: Wheaton Precious Metals Corp is far larger — about 21.6× AbCellera Biologics Inc's market cap, and Wheaton Precious Metals Corp pays a 0.7% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WPM | |
|---|---|---|
Market Cap | $2.35B | $50.76B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $165.72 |
52-Week Low | $2.78 | $86.72 |
Enterprise Value | $1.99B | $48.61B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Wheaton Precious Metals (WPM) trades at $111.89, down 3.32% recently amid broader precious metals volatility. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, supported by three consecutive quarterly EPS beats. Technical indicators signal bearish momentum with key support at $109, while analyst consensus remains strongly bullish with an $169 price target representing 51% upside potential from current levels.
WPM presents a compelling growth story with exceptional profitability margins (65.55% net income margin) and projected 2026 revenue growth to $2.7B. Primary risks include precious metal price volatility and geopolitical tensions affecting mining operations. The 80% buy rating from analysts suggests significant upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
